Trials / Completed
CompletedNCT05061693
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB054707 | Oral; Tablet |
| DRUG | Placebo | Oral; Tablet |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2023-08-11
- Completion
- 2024-02-28
- First posted
- 2021-09-29
- Last updated
- 2025-07-11
- Results posted
- 2024-08-27
Locations
49 sites across 6 countries: United States, Canada, Germany, Poland, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05061693. Inclusion in this directory is not an endorsement.